Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12493371 | 0.84 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12493454 | 0.78 | PDE5A (1.00) | PDE5A | |
| SCHEMBL15803420 | 0.76 | PDE5A (0.59) | PDE5A | |
| SCHEMBL12494881 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524151 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524148 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524132 | 0.75 | PDE5A (1.00) | PDE5A | |
| SCHEMBL6230657 | 0.73 | CA2 (0.71) | — | |
| SCHEMBL12524143 | 0.73 | PDE5A (1.00) | PDE5A | |
| SCHEMBL12524159 | 0.73 | PDE5A (1.00) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9388139-B2 | Derivatives of celeboxib, use thereof and preparation thereof | GERMAN UNIVERSITY (EG) | 2016-07-12 | — | — | US | disclosed |
| US-9388139-B2 | Derivatives of celeboxib, use thereof and preparation thereof | GERMAN UNIVERSITY (EG) | 2016-07-12 | — | — | US | disclosed |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2014-06-19 | — | — | US | disclosed |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE | 2014-06-19 | — | — | US | disclosed |
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | ALMIRALL, S.A. (ES) | 2014-06-19 | — | — | US | disclosed |
| WO-2012125884-A1 | DERIVATIVES OF CELECOXIB, USE THEREOF AND PREPARATION THEREOF | SOUTHERN RESEARCH INSTITUTE (US) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140170110-A1 | PYRIDIN-2(1H)-ONE DERIVATIVES USEFUL AS MEDICAMENTS FOR THE TREATMENT OF MYELOPROLIFERATIVE DISORDERS, TRANSPLANT REJECTION, IMMUNE-MEDIATED AND INFLAMMATORY DISEASES | JAK1, JAK3, JAK2 | PDE5A 1646/4885 |
| US-20140171477-A1 | DERIVATIVES OF CELEBOXIB, USE THEREOF AND PREPARATION THEREOF | PDE5A, PDE3A, PDE3B | PDE5A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.